A detailed history of Met Life Investment Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 56,707 shares of NBIX stock, worth $7.12 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
56,707
Previous 57,602 1.55%
Holding current value
$7.12 Million
Previous $7.93 Million 17.68%
% of portfolio
0.04%
Previous 0.05%

Shares

53 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $102,549 - $137,069
-895 Reduced 1.55%
56,707 $6.53 Million
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $131,121 - $143,476
-1,002 Reduced 1.71%
57,602 $7.93 Million
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $7.64 Million - $8.42 Million
58,604 New
58,604 $8.08 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $65,763 - $82,311
-620 Reduced 1.03%
59,348 $7.82 Million
Q3 2023

May 09, 2024

SELL
$94.02 - $117.1 $288,077 - $358,794
-3,064 Reduced 4.86%
59,968 $6.75 Million
Q3 2023

Apr 29, 2024

SELL
$94.02 - $117.1 $236,178 - $294,155
-2,512 Reduced 4.02%
59,968 $6.75 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $236,178 - $294,155
-2,512 Reduced 4.02%
59,968 $6.75 Million
Q2 2023

Apr 29, 2024

BUY
$89.53 - $104.87 $5.59 Million - $6.55 Million
62,480 New
62,480 $5.89 Million
Q2 2023

Aug 10, 2023

SELL
$89.53 - $104.87 $49,420 - $57,888
-552 Reduced 0.88%
62,480 $5.89 Million
Q1 2023

May 09, 2024

BUY
$94.11 - $123.02 $5.93 Million - $7.75 Million
63,032 New
63,032 $6.38 Billion
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $116,508 - $152,298
-1,238 Reduced 1.93%
63,032 $6.38 Million
Q4 2022

May 10, 2024

SELL
$106.72 - $127.06 $113,656 - $135,318
-1,065 Reduced 1.63%
64,270 $7.68 Million
Q4 2022

Jun 14, 2023

BUY
$106.72 - $127.06 $132,119 - $157,300
1,238 Added 1.96%
64,270 $7.68 Million
Q4 2022

Mar 22, 2023

SELL
$106.72 - $127.06 $113,656 - $135,318
-1,065 Reduced 1.63%
64,270 $7.68 Million
Q4 2022

Feb 15, 2023

SELL
$106.72 - $127.06 $113,656 - $135,318
-1,065 Reduced 1.63%
64,270 $7.68 Million
Q3 2022

May 10, 2024

SELL
$92.03 - $107.81 $62,856 - $73,634
-683 Reduced 1.03%
65,335 $6.94 Million
Q3 2022

Jun 14, 2023

BUY
$92.03 - $107.81 $211,945 - $248,286
2,303 Added 3.65%
65,335 $6.94 Million
Q3 2022

Mar 22, 2023

SELL
$92.03 - $107.81 $62,856 - $73,634
-683 Reduced 1.03%
65,335 $6.94 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $62,856 - $73,634
-683 Reduced 1.03%
65,335 $6.94 Million
Q2 2022

May 10, 2024

BUY
$75.79 - $100.07 $38,577 - $50,935
509 Added 0.78%
66,018 $6.44 Million
Q2 2022

Jun 20, 2023

BUY
$75.79 - $100.07 $226,308 - $298,809
2,986 Added 4.74%
66,018 $6.44 Million
Q2 2022

Mar 22, 2023

BUY
$75.79 - $100.07 $38,577 - $50,935
509 Added 0.78%
66,018 $6.44 Million
Q2 2022

Aug 11, 2022

BUY
$75.79 - $100.07 $38,577 - $50,935
509 Added 0.78%
66,018 $6.44 Million
Q1 2022

May 10, 2024

BUY
$72.45 - $94.81 $4.75 Million - $6.21 Million
65,509 New
65,509 $6.14 Million
Q1 2022

Jun 20, 2023

BUY
$72.45 - $94.81 $179,458 - $234,844
2,477 Added 3.93%
65,509 $6.14 Million
Q1 2022

Mar 22, 2023

BUY
$72.45 - $94.81 $1.42 Million - $1.85 Million
19,535 Added 42.49%
65,509 $6.14 Million
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $1.42 Million - $1.85 Million
19,535 Added 42.49%
65,509 $6.14 Million
Q4 2021

May 17, 2024

BUY
$79.65 - $106.22 $40,223 - $53,641
505 Added 1.11%
45,974 $3.92 Million
Q4 2021

Jun 21, 2023

SELL
$79.65 - $106.22 $1.36 Million - $1.81 Million
-17,058 Reduced 27.06%
45,974 $3.92 Million
Q4 2021

Mar 22, 2023

BUY
$79.65 - $106.22 $40,223 - $53,641
505 Added 1.11%
45,974 $3.92 Million
Q4 2021

Feb 15, 2022

BUY
$79.65 - $106.22 $40,223 - $53,641
505 Added 1.11%
45,974 $3.92 Million
Q3 2021

May 17, 2024

SELL
$86.18 - $99.03 $152,797 - $175,580
-1,773 Reduced 3.75%
45,469 $4.36 Million
Q3 2021

Jun 21, 2023

SELL
$86.18 - $99.03 $1.51 Million - $1.74 Million
-17,563 Reduced 27.86%
45,469 $4.36 Million
Q3 2021

Mar 22, 2023

SELL
$86.18 - $99.03 $152,797 - $175,580
-1,773 Reduced 3.75%
45,469 $4.36 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $152,797 - $175,580
-1,773 Reduced 3.75%
45,469 $4.36 Million
Q2 2021

May 17, 2024

SELL
$89.43 - $102.27 $114,828 - $131,314
-1,284 Reduced 2.65%
47,242 $4.6 Million
Q2 2021

Jun 21, 2023

SELL
$89.43 - $102.27 $1.41 Million - $1.61 Million
-15,790 Reduced 25.05%
47,242 $4.6 Million
Q2 2021

Mar 22, 2023

SELL
$89.43 - $102.27 $114,828 - $131,314
-1,284 Reduced 2.65%
47,242 $4.6 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $114,828 - $131,314
-1,284 Reduced 2.65%
47,242 $4.6 Million
Q1 2021

May 17, 2024

SELL
$87.57 - $119.4 $882,530 - $1.2 Million
-10,078 Reduced 17.2%
48,526 $4.72 Million
Q1 2021

Jun 26, 2023

SELL
$87.57 - $119.4 $1.27 Million - $1.73 Million
-14,506 Reduced 23.01%
48,526 $4.72 Billion
Q1 2021

Mar 22, 2023

BUY
$87.57 - $119.4 $4.24 Million - $5.78 Million
48,403 Added 39352.03%
48,526 $4.72 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $4.25 Million - $5.79 Million
48,526 New
48,526 $4.72 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $8,885 - $11,226
-123 Closed
0 $0
Q1 2019

Jul 13, 2023

SELL
$69.31 - $91.53 $4.36 Million - $5.76 Million
-62,909 Reduced 99.8%
123 $10,000
Q1 2019

Mar 22, 2023

BUY
$69.31 - $91.53 $69 - $91
1 Added 0.82%
123 $10,000
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $69 - $91
1 Added 0.82%
123 $11,000
Q4 2018

Jul 13, 2023

SELL
$68.32 - $124.36 $4.3 Million - $7.82 Million
-62,910 Reduced 99.81%
122 $8,000
Q4 2018

Mar 22, 2023

SELL
$68.32 - $124.36 $68 - $124
-1 Reduced 0.81%
122 $8,000
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $68 - $124
-1 Reduced 0.81%
122 $9,000
Q3 2018

Jul 13, 2023

SELL
$98.88 - $125.85 $6.22 Million - $7.92 Million
-62,909 Reduced 99.8%
123 $15,000
Q3 2018

Mar 22, 2023

SELL
$98.88 - $125.85 $6.34 Million - $8.07 Million
-64,147 Reduced 99.81%
123 $15,000
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $12,162 - $15,479
123 New
123 $15,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.